Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zoom
ZM
|
+$806M |
| 2 |
AbbVie
ABBV
|
+$481M |
| 3 |
T-Mobile US
TMUS
|
+$464M |
| 4 |
Kroger
KR
|
+$430M |
| 5 |
Baidu
BIDU
|
+$423M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.35B |
| 2 |
AGN
Allergan plc
AGN
|
+$1.26B |
| 3 |
S
Sprint Corporation
S
|
+$675M |
| 4 |
Amgen
AMGN
|
+$488M |
| 5 |
Humana
HUM
|
+$450M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 23.76% |
| 2 | Technology | 16.41% |
| 3 | Consumer Staples | 10.58% |
| 4 | Consumer Discretionary | 10.13% |
| 5 | Communication Services | 9.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
OMCC
1826
DELISTED
Old Market Capital Corp
OMCC
| $3.68M | ﹤0.01% |
496,943
-5,239
| -1% | -$33K |
|
|
SURF
1827
DELISTED
Surface Oncology, Inc. Common Stock
SURF
| $3.67M | ﹤0.01% |
559,337
+393,995
| +238% | +$1.42M |
|
1828
Verra Mobility
VRRM
$717M
| $3.66M | ﹤0.01% |
355,600
-276,100
| -44% | -$2.61M |
|
1829
RPC Inc
RES
$1.41B
| $3.65M | ﹤0.01% |
1,186,213
-706,636
| -37% | -$2.15M |
|
|
AZRE
1830
DELISTED
Azure Power Global Limited
AZRE
| $3.64M | ﹤0.01% |
228,285
+19,200
| +9% | +$289K |
|
1831
Electromed
ELMD
$341M
| $3.64M | ﹤0.01% |
236,304
+52,054
| +28% | +$720K |
|
|
SRT
1832
DELISTED
Startek Inc.
SRT
| $3.63M | ﹤0.01% |
714,700
-40,570
| -5% | -$160K |
|
1833
iShares Preferred and Income Securities ETF
PFF
$13.3B
| $3.62M | ﹤0.01% |
104,600
+82,000
| +363% | +$2.79M |
|
|
SUNE
1834
SUNation Energy
SUNE
$10.6M
| $3.62M | ﹤0.01% |
1
| – | – |
|
1835
Viasat
VSAT
$11.4B
| $3.62M | ﹤0.01% |
94,293
+62,100
| +193% | +$2.52M |
|
|
GRA
1836
DELISTED
W.R. Grace & Co.
GRA
| $3.61M | ﹤0.01% |
71,000
+6,000
| +9% | +$284K |
|
1837
Distribution Solutions Group
DSGR
$1.62B
| $3.58M | ﹤0.01% |
221,800
-42,400
| -16% | -$671K |
|
1838
State Street SPDR S&P Retail ETF
XRT
$640M
| $3.57M | ﹤0.01% |
+83,300
| New | +$3.16M |
|
1839
Advanced Energy
AEIS
$13.2B
| $3.57M | ﹤0.01% |
52,609
-278,878
| -84% | -$16.6M |
|
1840
Timken Company
TKR
$9.25B
| $3.57M | ﹤0.01% |
78,400
-135,738
| -63% | -$5.36M |
|
1841
NovaGold Resources
NG
$3.48B
| $3.55M | ﹤0.01% |
+387,671
| New | +$3.93M |
|
1842
Reading International Class A
RDI
$36.6M
| $3.55M | ﹤0.01% |
834,790
+59,000
| +8% | +$222K |
|
1843
Tactile Systems Technology
TCMD
$548M
| $3.55M | ﹤0.01% |
85,600
+12,700
| +17% | +$595K |
|
|
TUP
1844
DELISTED
Tupperware Brands Corporation
TUP
| $3.55M | ﹤0.01% |
746,559
-169,353
| -18% | -$564K |
|
1845
Heron Therapeutics
HRTX
$63.9M
| $3.53M | ﹤0.01% |
239,800
-812,092
| -77% | -$13.3M |
|
1846
Pure Cycle
PCYO
$271M
| $3.52M | ﹤0.01% |
383,500
+180,300
| +89% | +$1.76M |
|
1847
Natural Alternatives International
NAII
$12.8M
| $3.52M | ﹤0.01% |
514,263
-9,858
| -2% | -$66.9K |
|
1848
The GEO Group
GEO
$4.11B
| $3.52M | ﹤0.01% |
+297,123
| New | +$3.63M |
|
1849
CEMIG Preferred Shares
CIG
$5.52B
| $3.51M | ﹤0.01% |
3,355,994
+719,601
| +27% | +$684K |
|
1850
A.O. Smith
AOS
$8.45B
| $3.5M | ﹤0.01% |
74,300
+64,200
| +636% | +$2.8M |
|
Similar funds
Jim Simons's Q2 2020 Portfolio in Review
As of Q2 2020, Jim Simons held 3,987 positions worth $116B, up 13% from $103B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Jim Simons withdrew a net $8.24B in Q2 2020, closing 596 positions and reducing 1,366 holdings. Its most notable exit was Allergan plc, an estimated $1.26B position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 24% of assets, down from 26% a quarter earlier, followed by Technology and Consumer Staples.
Against the trend, Jim Simons opened a new position in Uber worth $187M.
- Jim Simons's largest Q2 2020 buy was Uber: 6,030,316 shares worth $187M.
- Jim Simons added most to Zoom in Q2 2020, an estimated $806M increase.
- Jim Simons's biggest Q2 2020 reduction was Bristol-Myers Squibb, cutting an estimated $1.35B.
- Jim Simons fully exited Allergan plc in Q2 2020, selling an estimated $1.26B.
- Jim Simons's ten largest holdings make up 14% of its $116B portfolio in Q2 2020.
- Jim Simons opened 584 new positions and closed 596 in Q2 2020.
- Jim Simons's portfolio value rose 13% quarter-over-quarter to $116B.
Based on Renaissance Technologies's 13F filing for Q2 2020, filed 13 Aug 2020.